Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Later, patients using these drugs reported unexpected weight loss due to reduced appetite, which shifted their use from diabetes treatment to mainstream weight-management therapy
Has already launched oral GLP-1 diabetes drug Liraglutide in the UK, demonstrating early market presence
Why it matters: Research shows proper protein intake can reduce muscle loss from 40% to under 25% of total weight lost on GLP-1 medications
until noon and it wreaked total havoc on my body
By The Numbers Total Revenue: $71.7 billion ($67.2 billion in Q2 2025) Net Income: $1.66 billion ($1.53 billion in Q2 2025) Earnings Per Share: Adjusted after-tax income of $7.78 ($7.20 in Q2 2025) Share Repurchases: $250 million in Q2 2026 Dividend Declared: $1.56 per share in Q2 2026 Stock Price Movement: Shares dropped 2% to $290.20 Thursday afternoon
